In contrast, studies have shown that low-dose glibenclamide (a type 2 diabetes drug that inhibits K-ATP channels in pancreatic β cells) downregulates TGF-β1, NLRP3, ASC, TGF-β1, NLRP3, and ASC expression induced by thioacetamide (Table 1). Here, TGFB1 is linked to type 2 diabetes mellitus.